SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI
Abstract Background Taking statins for a long time is associated with an increased risk of new-onset diabetes mellitus. Sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce insulin resistance and improve pancreatic β-cell function. Methods and results In total, 333 non-diabetes patients with...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-06-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12872-023-03353-1 |